Bacterial Ghosts as Innovative Transport Vehicles for Platinum-Based Anticancer Drugs

Area of Science:

• Biotechnology
• Nanotechnology
• Oncology

Background:

• Platinum-based anticancer drugs like oxaliplatin (OXA) are effective but limited by severe toxicities and drug resistance.
• Oxaliplatin is crucial for colorectal cancer but restricted by dose-dependent adverse effects.

Purpose of the Study:

• To develop novel drug carriers using bacterial ghosts (BGs) for OXA and its derivatives.
• To evaluate the physicochemical properties, stability, and in vitro anticancer activity of OXA-loaded BG formulations.

Main Methods:

• Loading of OXA and derivatives into BGs derived from Escherichia coli strains.
• Quantification of platinum content using inductively coupled plasma mass spectrometry.
• Characterization of physicochemical properties via FPLC, electron microscopy, EELS, and flow cytometry.
• Assessment of formulation stability under various conditions for up to 120 days.

Main Results:

• Successful encapsulation of OXA and derivatives into BGs with high batch-to-batch reproducibility.
• Characterization confirmed the physicochemical integrity of the loaded formulations.
• Bacterial encapsulation preserved the in vitro anticancer activity of the platinum compounds.
• Formulations showed stability over 120 days in different media and storage conditions.

Conclusions:

• Bacterial ghosts serve as effective carriers for platinum-based anticancer drugs like oxaliplatin.
• This novel drug delivery system shows promise for enhancing cancer therapy by maintaining drug efficacy.
• Further research may explore reduced toxicity and improved clinical outcomes with BG-encapsulated platinum compounds.